Tarsus Pharmaceuticals, Inc. logo TARS - Tarsus Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
1
BUY 7
HOLD 1
SELL 0
STRONG
SELL
0
| PRICE TARGET: $84.00 DETAILS
HIGH: $100.00
LOW: $68.00
MEDIAN: $84.00
CONSENSUS: $84.00
UPSIDE: 34.92%

About Tarsus Pharmaceuticals, Inc. (https://www.tarsusrx.com)

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Key Executives

NAME TITLE DOB SALARY
Bobak R. Azamian Co-Founder, President, Chief Executive Officer & Chairman $1,318,208 USD
Jeffrey S. Farrow Chief Financial Officer & Chief Strategy Officer 1962 $888,645 USD
Seshadri Neervannan Chief Operating Officer 1968 $839,200 USD
Aziz Mottiwala Chief Commercial Officer 1978 $821,650 USD
Bryan Wahl General Counsel & Corporate Secretary 1978 $771,233 USD
Dianne C. Whitfield Chief Human Resources Officer 1977 $578,900 USD
Elizabeth Yeu Chief Medical Officer 1979 $156,691 USD
Adrienne Kemp Senior Director of Corporate Communications
Cara Miller Senior Vice President of Corporate Affairs
David Nakasone Head of Investor Relations
Matthew Rossen Vice President of Marketing 1978
Neera Clase Senior Vice President of Market Access
Scott Youmans Vice President of Sales

Company Peers

Peer analysis pending, check back in 1-2 minutes.